Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VLX600 in refractory advanced solid tumors
NCT02222363Phase 1Terminated
- Sponsor
- Vivolux
- Start
- Feb 2015
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vlx600 in solid tumor (advanced stage), sponsored by Vivolux. Primary endpoints: Assessment of adverse event profile, Maximum Tolerated Dose up to 1 year and 1 more. Started Feb 2015; status: terminated.
02
Drugs
vlx600
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02222363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02222363.